A group of investors led a $22m Series B funding round in Stilla Technologies, a provider of pioneering digital PCR (dPCR) solutions. The round included TUS-Holdings, Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and Idinvest Partners. "We will use the funds to boost the development of our next-generation solution, which will feature superior analytical performance including 6-color detection capabilities. Our future focus will be to apply our state-of-the-art technology to clinical diagnostics, to the benefit of patients. By bringing TUS-Holdings on board, we also look to rapidly expand our activities in China and throughout Asia, while maintaining strong growth of the business in Europe and the United States. Following our Series A round in October 2018, the company has been expanding very rapidly, experiencing strong sales growth and making exciting progress with its pipeline of new products. The new Series B round will allow us to continue on this successful course at an even faster pace," Rémi Dangla, Stilla Technologies Co-Founder and CEO.